Loading
A Seattle trial that tested whether giving the chemotherapy drug fludarabine before an infusion of a patient's own melanoma-targeting T cells helped the cells survive. The published report found they lasted about three times longer.
The registry describes a phase I study of autologous CD8+ antigen-specific T-cell clones following fludarabine lymphodepletion in metastatic melanoma, started in May 2003 and completed in October 2008, with an estimated enrolment of 12; Cassian Yee is listed as principal investigator (ClinicalTrials.gov NCT00317759). The trial's report, which names this registration (FHCRC 1796), gave 19 infusions to 10 patients and found that fludarabine extended median persistence of the transferred clones from 4.5 to 13.0 days (PLoS ONE 2009). No results are posted on the registry.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/